Public dataset
Recorded source agreement and disagreement
Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.
- Public rows
- 1,681
- Generated
- Schema version
- source-consensus/2
Coverage
What this run contains
- Compared medicine fields
- 1,681
- Agree
- 1,282
- Differ
- 0
- Not comparable
- 12
- Insufficient context
- 387
- Fields represented
- 5
- bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
Method
How the rows were made
- Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
- One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
- Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
- not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
- The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
- Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
- documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.
Limits
Read these before using a row
- Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
- The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
- Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
- Only the recorded fields and source documents in this snapshot are compared.
- A source count is the number of retained source records in the row, not a count of independent experiments.
Provenance
Source examples
abacavir · bioavailability · agree
15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)The geometric mean absolute bioavailability of the tablet was 83%.
alemtuzumab · volumeOfDistribution · not_comparable
2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).
abiraterone · halfLife · insufficient_context
31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| field | string | Recorded pharmacokinetic field being compared. |
| comparisonState | string | agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero. |
| comparisonReasons | string[] | Deterministic codes explaining the state. |
| documentsExamined | number | Recorded source documents considered for the field. |
| sourceCount | number | Recorded source readings represented. |
| agreementRate | number | Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability. |
| readings | consensus-reading[] | Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt. |
Reader
Search and filter the rows
Showing 401–410 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 401
- Medicine slug
- desoximetasone
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 33
- Source count
- 12
- Agreement rate
- 1
- Recorded readings
15 ± 2 hours
- Numeric value
- 15
- Unit
- hours
- Source records
- 12
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 12 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:54743c9d-badd-47ce-bf86-6a8c398f7f07 (opens source in a new tab)
Desoximetasone label
Version not recorded · Effective date not recorded
The half-life of the material was 15 ± 2 hours (for urine) and 17 ± 2 hours (for feces) between the third and fifth trial day.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0e72952e-8e9f-467a-8191-2bc157087d60 (opens source in a new tab)
Desoximetasone label
Version not recorded · Effective date not recorded
The half-life of the material was 15 ± 2 hours (for urine) and 17 ± 2 hours (for feces) between the third and fifth trial day.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:302fc53a-2779-4168-b76c-9ae0cf0b3331 (opens source in a new tab)
Desoximetasone label
Version not recorded · Effective date not recorded
The half-life of the material was 15 ± 2 hours (for urine) and 17 ± 2 hours (for feces) between the third and fifth trial day.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f53ddb86-bf8a-4bb3-b7ce-387fa78d9066 (opens source in a new tab)
Desoximetasone label
Version not recorded · Effective date not recorded
The half-life of the material was 15 ± 2 hours (for urine) and 17 ± 2 hours (for feces) between the third and fifth trial day.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:309a93de-ce89-4244-959a-3236d5e95c06 (opens source in a new tab)
Desoximetasone label
Version not recorded · Effective date not recorded
The half-life of the material was 15 ± 2 hours (for urine) and 17 ± 2 hours (for feces) between the third and fifth trial day.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f30b6fcc-43bc-4d65-9c3b-8d6ca780a024 (opens source in a new tab)
Desoximetasone label
Version not recorded · Effective date not recorded
The half-life of the material was 15 ± 2 hours (for urine) and 17 ± 2 hours (for feces) between the third and fifth trial day.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c84c7168-3d46-4e05-a25c-3d594ff94268 (opens source in a new tab)
Desoximetasone label
Version not recorded · Effective date not recorded
The half-life of the material was 15 ± 2 hours (for urine) and 17 ± 2 hours (for feces) between the third and fifth trial day.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4ad6c159-4daa-4a33-8db6-351b5263323d (opens source in a new tab)
Desoximetasone label
Version not recorded · Effective date not recorded
The half-life of the material was 15 ± 2 hours (for urine) and 17 ± 2 hours (for feces) between the third and fifth trial day.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:da2a8a3e-f187-4906-8fe3-246cc31de16f (opens source in a new tab)
Desoximetasone label
Version not recorded · Effective date not recorded
The half-life of the material was 15 ± 2 hours (for urine) and 17 ± 2 hours (for feces) between the third and fifth trial day.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:827aee22-cf48-477c-8791-c74f16da954d (opens source in a new tab)
Desoximetasone label
Version not recorded · Effective date not recorded
The half-life of the material was 15 ± 2 hours (for urine) and 17 ± 2 hours (for feces) between the third and fifth trial day.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4f90b0cd-9443-4940-8781-1a05e42ccbb8 (opens source in a new tab)
Desoximetasone label
Version not recorded · Effective date not recorded
The half-life of the material was 15 ± 2 hours (for urine) and 17 ± 2 hours (for feces) between the third and fifth trial day.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:37eb1205-1743-4480-8631-b0bbcaeb8359 (opens source in a new tab)
Desoximetasone label
Version not recorded · Effective date not recorded
The half-life of the material was 15 ± 2 hours (for urine) and 17 ± 2 hours (for feces) between the third and fifth trial day.
Projected row 402
- Medicine slug
- desvenlafaxine
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 44
- Source count
- 33
- Agreement rate
- 1
- Recorded readings
80%
- Numeric value
- 80
- Unit
- %
- Source records
- 33
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 33 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:25bdfc41-c7cb-4d16-b6a8-f102f9b8c984 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Absorption The absolute oral bioavailability of desvenlafaxine after oral administration is about 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7ee04e8c-ce6c-450d-9122-2bffd170bfd7 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Absorption The absolute oral bioavailability of desvenlafaxine after oral administration is about 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:56c9e8ee-1460-4a4c-8033-65d9afb358c8 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Absorption The absolute oral bioavailability of desvenlafaxine after oral administration is about 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:662890ff-d254-40e0-a9fe-f07ab94d65d6 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Absorption The absolute oral bioavailability of desvenlafaxine after oral administration is about 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:44f4b928-d5b8-44e7-bfa6-81fb0dc1a718 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Absorption The absolute oral bioavailability of desvenlafaxine after oral administration is about 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:325be002-4db2-40e9-e063-6394a90ae94e (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Absorption The absolute oral bioavailability of desvenlafaxine after oral administration is about 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:453a5759-2f0d-421d-be78-81ab97c8ce77 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Absorption The absolute oral bioavailability of desvenlafaxine after oral administration is about 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1d8889c9-9403-4b4b-8abd-7dc9a9fc1816 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Absorption The absolute oral bioavailability of desvenlafaxine after oral administration is about 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aca478a7-eff6-4cd5-93a8-2dca69883a4b (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Absorption The absolute oral bioavailability of desvenlafaxine after oral administration is about 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4b786ea1-309d-440c-b091-38d6b1f7fbd3 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Absorption The absolute oral bioavailability of desvenlafaxine after oral administration is about 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b4a5efab-3765-4ea5-a8cd-66e67e76c845 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Absorption The absolute oral bioavailability of desvenlafaxine after oral administration is about 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:91cf39c9-4d26-480a-a3a3-a3d8d4c4d222 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Absorption The absolute oral bioavailability of desvenlafaxine after oral administration is about 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a6c2316d-2a51-4975-a061-dc72f2724b2f (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Absorption The absolute oral bioavailability of desvenlafaxine after oral administration is about 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d4542c5e-f9e8-49c7-afa6-9dd4c4d485f2 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Absorption The absolute oral bioavailability of desvenlafaxine after oral administration is about 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f99c78ef-5a0a-45af-9b4b-5a78b75fe994 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Absorption The absolute oral bioavailability of desvenlafaxine after oral administration is about 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:edf18b33-a226-44f8-9f42-c409e691ee64 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Absorption The absolute oral bioavailability of desvenlafaxine after oral administration is about 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:593d340b-f49a-455b-aeb2-5a1eaf7b6cbe (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Absorption The absolute oral bioavailability of desvenlafaxine after oral administration is about 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e0dbbdbc-9438-407a-b3e1-f3bb7f177a4e (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Absorption: The absolute oral bioavailability of desvenlafaxine after oral administration is about 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d585d916-2a5d-4baa-9c64-52b12313aba3 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Absorption The absolute oral bioavailability of desvenlafaxine after oral administration is about 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b2a3edb8-ba64-4ead-b452-d6c8dbaba91d (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Absorption The absolute oral bioavailability of desvenlafaxine after oral administration is about 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7107a864-fcb3-4cbf-9fcb-061bef13be2d (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Absorption The absolute oral bioavailability of desvenlafaxine after oral administration is about 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fd08efc0-6109-46ee-9556-f77b3f7b6baf (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Absorption The absolute oral bioavailability of desvenlafaxine after oral administration is about 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:88ac1206-864b-47a3-82ab-be83bc9532f3 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Absorption The absolute oral bioavailability of desvenlafaxine after oral administration is about 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b3ef2bb2-c336-2d57-e053-2995a90a5fe0 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Absorption The absolute oral bioavailability of desvenlafaxine after oral administration is about 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5755f1b2-c10b-47f6-a08d-38d1c05bd353 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Absorption The absolute oral bioavailability of desvenlafaxine after oral administration is about 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9f74708c-6f6a-46cf-8c79-87a25c2bb6f8 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Absorption and distribution The absolute oral bioavailability of desvenlafaxine after oral administration is about 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5bd203d2-477e-4d12-a875-cb8009f42410 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Absorption The absolute oral bioavailability of desvenlafaxine after oral administration is about 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0f43610c-f290-46ea-d186-4f998ed99fce (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Absorption The absolute oral bioavailability of PRISTIQ after oral administration is about 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e96272a2-8f73-4fbe-a8d4-a78d4ad68831 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Absorption The absolute oral bioavailability of desvenlafaxine after oral administration is about 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6741bdef-dc58-47be-b28d-c43476dc8bde (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Absorption The absolute oral bioavailability of desvenlafaxine after oral administration is about 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c7c77c4d-dd04-4780-9fa4-8fea30aff8f9 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Absorption The absolute oral bioavailability of desvenlafaxine after oral administration is about 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5e78c812-7fe6-4a4e-8465-0415df2e9851 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Absorption The absolute oral bioavailability of desvenlafaxine after oral administration is about 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5f349cc5-b803-462d-b323-d681bd1a02f0 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Absorption The absolute oral bioavailability of desvenlafaxine after oral administration is about 80%.
Projected row 403
- Medicine slug
- desvenlafaxine
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 44
- Source count
- 44
- Agreement rate
- 1
- Recorded readings
30%
- Numeric value
- 30
- Unit
- %
- Source records
- 44
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 44 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:25bdfc41-c7cb-4d16-b6a8-f102f9b8c984 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Plasma protein binding of desvenlafaxine is 30% and is independent of drug concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7ee04e8c-ce6c-450d-9122-2bffd170bfd7 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Plasma protein binding of desvenlafaxine is 30% and is independent of drug concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:56c9e8ee-1460-4a4c-8033-65d9afb358c8 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Plasma protein binding of desvenlafaxine is 30% and is independent of drug concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:662890ff-d254-40e0-a9fe-f07ab94d65d6 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Plasma protein binding of desvenlafaxine is 30% and is independent of drug concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:44f4b928-d5b8-44e7-bfa6-81fb0dc1a718 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Plasma protein binding of desvenlafaxine is 30% and is independent of drug concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b14695b4-c35e-4902-8144-d31d698b1c58 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Plasma protein binding of desvenlafaxine is 30% and is independent of drug concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:325be002-4db2-40e9-e063-6394a90ae94e (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Plasma protein binding of desvenlafaxine is 30% and is independent of drug concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2dce1542-ead5-1b24-e063-6294a90a6df0 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Plasma protein binding of desvenlafaxine is 30% and is independent of drug concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:453a5759-2f0d-421d-be78-81ab97c8ce77 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Plasma protein binding of desvenlafaxine is 30% and is independent of drug concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1d8889c9-9403-4b4b-8abd-7dc9a9fc1816 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Plasma protein binding of desvenlafaxine is 30% and is independent of drug concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ff837eb1-24c3-4c63-9b4b-c6b5935a9b47 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Plasma protein binding of desvenlafaxine is 30% and is independent of drug concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aca478a7-eff6-4cd5-93a8-2dca69883a4b (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Plasma protein binding of desvenlafaxine is 30% and is independent of drug concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4b786ea1-309d-440c-b091-38d6b1f7fbd3 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Plasma protein binding of desvenlafaxine is 30% and is independent of drug concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:65f4a870-aa91-4d05-a32d-a161295bcc17 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Plasma protein binding of desvenlafaxine is 30% and is independent of drug concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b4a5efab-3765-4ea5-a8cd-66e67e76c845 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Plasma protein binding of desvenlafaxine is 30% and is independent of drug concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:91cf39c9-4d26-480a-a3a3-a3d8d4c4d222 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Plasma protein binding of desvenlafaxine is 30% and is independent of drug concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:643bfe62-7885-4db4-9fff-5d8552b53d14 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Plasma protein binding of desvenlafaxine is 30% and is independent of drug concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a6c2316d-2a51-4975-a061-dc72f2724b2f (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Plasma protein binding of desvenlafaxine is 30% and is independent of drug concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:48d3a09e-850d-472d-8fb2-996a5167b16d (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Plasma protein binding of desvenlafaxine is 30% and is independent of drug concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5b6e86bc-24a3-4f8c-aff7-6e1e17a7d1a4 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Plasma protein binding of desvenlafaxine is 30% and is independent of drug concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d4542c5e-f9e8-49c7-afa6-9dd4c4d485f2 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Plasma protein binding of desvenlafaxine is 30% and is independent of drug concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f99c78ef-5a0a-45af-9b4b-5a78b75fe994 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Plasma protein binding of desvenlafaxine is 30% and is independent of drug concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:edf18b33-a226-44f8-9f42-c409e691ee64 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Plasma protein binding of desvenlafaxine is 30% and is independent of drug concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:593d340b-f49a-455b-aeb2-5a1eaf7b6cbe (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Plasma protein binding of desvenlafaxine is 30% and is independent of drug concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:617476f9-62d7-40ef-a1b1-c349d4ad706f (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Plasma protein binding of desvenlafaxine is 30% and is independent of drug concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e0dbbdbc-9438-407a-b3e1-f3bb7f177a4e (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Plasma protein binding of desvenlafaxine is 30% and is independent of drug concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d585d916-2a5d-4baa-9c64-52b12313aba3 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Plasma protein binding of desvenlafaxine is 30% and is independent of drug concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b2a3edb8-ba64-4ead-b452-d6c8dbaba91d (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Plasma protein binding of desvenlafaxine is 30% and is independent of drug concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7107a864-fcb3-4cbf-9fcb-061bef13be2d (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Plasma protein binding of desvenlafaxine is 30% and is independent of drug concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fd08efc0-6109-46ee-9556-f77b3f7b6baf (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Plasma protein binding of desvenlafaxine is 30% and is independent of drug concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:88ac1206-864b-47a3-82ab-be83bc9532f3 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Plasma protein binding of desvenlafaxine is 30% and is independent of drug concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b3ef2bb2-c336-2d57-e053-2995a90a5fe0 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Plasma protein binding of desvenlafaxine is 30% and is independent of drug concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5a136b61-f734-43d5-86fc-059ff3b5342a (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Plasma protein binding of desvenlafaxine is 30% and is independent of drug concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5755f1b2-c10b-47f6-a08d-38d1c05bd353 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Plasma protein binding of desvenlafaxine is 30% and is independent of drug concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9f74708c-6f6a-46cf-8c79-87a25c2bb6f8 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
The plasma protein binding of desvenlafaxine is low (30%) and is independent of drug concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5bd203d2-477e-4d12-a875-cb8009f42410 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Plasma protein binding of desvenlafaxine is 30% and is independent of drug concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0f43610c-f290-46ea-d186-4f998ed99fce (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Plasma protein binding of desvenlafaxine is 30% and is independent of drug concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e96272a2-8f73-4fbe-a8d4-a78d4ad68831 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Plasma protein binding of desvenlafaxine is 30% and is independent of drug concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6741bdef-dc58-47be-b28d-c43476dc8bde (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Plasma protein binding of desvenlafaxine is 30% and is independent of drug concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c7c77c4d-dd04-4780-9fa4-8fea30aff8f9 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Plasma protein binding of desvenlafaxine is 30% and is independent of drug concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5e78c812-7fe6-4a4e-8465-0415df2e9851 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Plasma protein binding of desvenlafaxine is 30% and is independent of drug concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3fcc0555-f9cf-4735-a0ef-830c50c390b8 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Plasma protein binding of desvenlafaxine is 30% and is independent of drug concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5f349cc5-b803-462d-b323-d681bd1a02f0 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Plasma protein binding of desvenlafaxine is 30% and is independent of drug concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:387cea91-6924-2a68-e063-6394a90a8f75 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Plasma protein binding of desvenlafaxine is 30% and is independent of drug concentration.
Projected row 404
- Medicine slug
- desvenlafaxine
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 44
- Source count
- 44
- Agreement rate
- 1
- Recorded readings
3.4 L/kg
- Numeric value
- 3.4
- Unit
- L/kg
- Source records
- 44
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 44 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:25bdfc41-c7cb-4d16-b6a8-f102f9b8c984 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Distribution Steady-state volume of distribution of desvenlafaxine is 3.4 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7ee04e8c-ce6c-450d-9122-2bffd170bfd7 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Distribution Steady-state volume of distribution of desvenlafaxine is 3.4 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:56c9e8ee-1460-4a4c-8033-65d9afb358c8 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Distribution Steady-state volume of distribution of desvenlafaxine is 3.4 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:662890ff-d254-40e0-a9fe-f07ab94d65d6 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Distribution Steady-state volume of distribution of desvenlafaxine is 3.4 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:44f4b928-d5b8-44e7-bfa6-81fb0dc1a718 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Distribution Steady-state volume of distribution of desvenlafaxine is 3.4 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b14695b4-c35e-4902-8144-d31d698b1c58 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Distribution Steady-state volume of distribution of desvenlafaxine is 3.4 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:325be002-4db2-40e9-e063-6394a90ae94e (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Distribution Steady-state volume of distribution of desvenlafaxine is 3.4 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2dce1542-ead5-1b24-e063-6294a90a6df0 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Distribution Steady-state volume of distribution of desvenlafaxine is 3.4 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:453a5759-2f0d-421d-be78-81ab97c8ce77 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Distribution Steady-state volume of distribution of desvenlafaxine is 3.4 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1d8889c9-9403-4b4b-8abd-7dc9a9fc1816 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Distribution Steady-state volume of distribution of desvenlafaxine is 3.4 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ff837eb1-24c3-4c63-9b4b-c6b5935a9b47 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Distribution Steady-state volume of distribution of desvenlafaxine is 3.4 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aca478a7-eff6-4cd5-93a8-2dca69883a4b (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Distribution Steady-state volume of distribution of desvenlafaxine is 3.4 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4b786ea1-309d-440c-b091-38d6b1f7fbd3 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Distribution Steady-state volume of distribution of desvenlafaxine is 3.4 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:65f4a870-aa91-4d05-a32d-a161295bcc17 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Distribution Steady-state volume of distribution of desvenlafaxine is 3.4 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b4a5efab-3765-4ea5-a8cd-66e67e76c845 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Distribution Steady-state volume of distribution of desvenlafaxine is 3.4 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:91cf39c9-4d26-480a-a3a3-a3d8d4c4d222 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Distribution Steady-state volume of distribution of desvenlafaxine is 3.4 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:643bfe62-7885-4db4-9fff-5d8552b53d14 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Distribution Steady-state volume of distribution of desvenlafaxine is 3.4 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a6c2316d-2a51-4975-a061-dc72f2724b2f (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Distribution Steady-state volume of distribution of desvenlafaxine is 3.4 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:48d3a09e-850d-472d-8fb2-996a5167b16d (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Distribution Steady-state volume of distribution of desvenlafaxine is 3.4 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5b6e86bc-24a3-4f8c-aff7-6e1e17a7d1a4 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Distribution Steady-state volume of distribution of desvenlafaxine is 3.4 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d4542c5e-f9e8-49c7-afa6-9dd4c4d485f2 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Distribution Steady-state volume of distribution of desvenlafaxine is 3.4 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f99c78ef-5a0a-45af-9b4b-5a78b75fe994 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Distribution Steady-state volume of distribution of desvenlafaxine is 3.4 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:edf18b33-a226-44f8-9f42-c409e691ee64 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Distribution Steady-state volume of distribution of desvenlafaxine is 3.4 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:593d340b-f49a-455b-aeb2-5a1eaf7b6cbe (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Distribution Steady-state volume of distribution of desvenlafaxine is 3.4 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:617476f9-62d7-40ef-a1b1-c349d4ad706f (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Distribution Steady-state volume of distribution of desvenlafaxine is 3.4 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e0dbbdbc-9438-407a-b3e1-f3bb7f177a4e (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Distribution : Steady-state volume of distribution of desvenlafaxine is 3.4 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d585d916-2a5d-4baa-9c64-52b12313aba3 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Distribution Steady-state volume of distribution of desvenlafaxine is 3.4 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b2a3edb8-ba64-4ead-b452-d6c8dbaba91d (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Distribution Steady-state volume of distribution of desvenlafaxine is 3.4 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7107a864-fcb3-4cbf-9fcb-061bef13be2d (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Distribution Steady-state volume of distribution of desvenlafaxine is 3.4 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fd08efc0-6109-46ee-9556-f77b3f7b6baf (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Distribution Steady-state volume of distribution of desvenlafaxine is 3.4 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:88ac1206-864b-47a3-82ab-be83bc9532f3 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Distribution Steady-state volume of distribution of desvenlafaxine is 3.4 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b3ef2bb2-c336-2d57-e053-2995a90a5fe0 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Distribution Steady-state volume of distribution of desvenlafaxine is 3.4 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5a136b61-f734-43d5-86fc-059ff3b5342a (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Distribution Steady-state volume of distribution of desvenlafaxine is 3.4 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5755f1b2-c10b-47f6-a08d-38d1c05bd353 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Distribution Steady-state volume of distribution of desvenlafaxine is 3.4 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9f74708c-6f6a-46cf-8c79-87a25c2bb6f8 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
The desvenlafaxine volume of distribution at steady-state following intravenous administration is 3.4 L/kg, indicating distribution into nonvascular compartments.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5bd203d2-477e-4d12-a875-cb8009f42410 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Distribution Steady-state volume of distribution of desvenlafaxine is 3.4 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0f43610c-f290-46ea-d186-4f998ed99fce (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Distribution Steady-state volume of distribution of desvenlafaxine is 3.4 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e96272a2-8f73-4fbe-a8d4-a78d4ad68831 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Distribution Steady-state volume of distribution of desvenlafaxine is 3.4 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6741bdef-dc58-47be-b28d-c43476dc8bde (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Distribution Steady-state volume of distribution of desvenlafaxine is 3.4 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c7c77c4d-dd04-4780-9fa4-8fea30aff8f9 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Distribution Steady-state volume of distribution of desvenlafaxine is 3.4 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5e78c812-7fe6-4a4e-8465-0415df2e9851 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Distribution Steady-state volume of distribution of desvenlafaxine is 3.4 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3fcc0555-f9cf-4735-a0ef-830c50c390b8 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Distribution Steady-state volume of distribution of desvenlafaxine is 3.4 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5f349cc5-b803-462d-b323-d681bd1a02f0 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Distribution Steady-state volume of distribution of desvenlafaxine is 3.4 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:387cea91-6924-2a68-e063-6394a90a8f75 (opens source in a new tab)
Desvenlafaxine label
Version not recorded · Effective date not recorded
Distribution Steady-state volume of distribution of desvenlafaxine is 3.4 L/kg.
Projected row 405
- Medicine slug
- dexlansoprazole
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 15
- Source count
- 15
- Agreement rate
- 1
- Recorded readings
96 to 99%
- Numeric value
- 96
- Unit
- %
- Source records
- 15
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 15 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:caad4ada-2cf9-4e12-99df-6ca4388cf0f6 (opens source in a new tab)
Dexlansoprazole label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of dexlansoprazole ranged from 96 to 99% in healthy subjects and was independent of concentration from 0.01 to 20 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fc3de800-bfad-4e2f-b664-d58a67550b2f (opens source in a new tab)
Dexlansoprazole label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of dexlansoprazole ranged from 96 to 99% in healthy subjects and was independent of concentration from 0.01 to 20 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dcfe880a-b96d-4a3c-aa21-3998d0bcfe9e (opens source in a new tab)
Dexlansoprazole label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of dexlansoprazole ranged from 96 to 99% in healthy subjects and was independent of concentration from 0.01 to 20 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d7452a26-db20-42fc-868a-a3e3606ca895 (opens source in a new tab)
Dexlansoprazole label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of dexlansoprazole ranged from 96 to 99% in healthy subjects and was independent of concentration from 0.01 to 20 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7c7698da-3cda-4301-ae93-02fb64b9c90d (opens source in a new tab)
Dexlansoprazole label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of dexlansoprazole ranged from 96 to 99% in healthy subjects and was independent of concentration from 0.01 to 20 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8dca4887-c75a-4021-8564-b704e9e1fa3e (opens source in a new tab)
Dexlansoprazole label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of dexlansoprazole ranged from 96 to 99% in healthy subjects and was independent of concentration from 0.01 to 20 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:59e0c5d7-12e9-b5d7-e063-6394a90a7366 (opens source in a new tab)
Dexlansoprazole label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of dexlansoprazole ranged from 96 to 99% in healthy subjects and was independent of concentration from 0.01 to 20 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3f9699b5-7614-41cb-bd1d-ff02930e98f3 (opens source in a new tab)
Dexlansoprazole label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of dexlansoprazole ranged from 96 to 99% in healthy subjects and was independent of concentration from 0.01 to 20 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9819f033-3bbe-442e-8e92-45fec77b237d (opens source in a new tab)
Dexlansoprazole label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of dexlansoprazole ranged from 96 to 99% in healthy subjects and was independent of concentration from 0.01 to 20 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4f44e84f-6219-4445-a67d-df37d18b014d (opens source in a new tab)
Dexlansoprazole label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of dexlansoprazole ranged from 96 to 99% in healthy subjects and was independent of concentration from 0.01 to 20 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:31d3d485-5f87-4405-b940-490fa4ccf9cc (opens source in a new tab)
Dexlansoprazole label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of dexlansoprazole ranged from 96 to 99% in healthy subjects and was independent of concentration from 0.01 to 20 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:24c33ba6-bf47-434e-903e-f7ced98e030e (opens source in a new tab)
Dexlansoprazole label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of dexlansoprazole ranged from 96 to 99% in healthy subjects and was independent of concentration from 0.01 to 20 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f9607c88-03b7-46c6-8b88-84f01dcf2221 (opens source in a new tab)
Dexlansoprazole label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of dexlansoprazole ranged from 96 to 99% in healthy subjects and was independent of concentration from 0.01 to 20 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3ed69e5a-aa78-4118-aa32-59a10f80c901 (opens source in a new tab)
Dexlansoprazole label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of dexlansoprazole ranged from 96 to 99% in healthy subjects and was independent of concentration from 0.01 to 20 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f799b9b6-ba79-f335-e053-6294a90aaa68 (opens source in a new tab)
Dexlansoprazole label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of dexlansoprazole ranged from 96 to 99% in healthy subjects and was independent of concentration from 0.01 to 20 mcg/mL.
Projected row 406
- Medicine slug
- dexlansoprazole
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 15
- Source count
- 15
- Agreement rate
- 1
- Recorded readings
0.7 hours
- Numeric value
- 0.7
- Unit
- hours
- Source records
- 15
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 15 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:caad4ada-2cf9-4e12-99df-6ca4388cf0f6 (opens source in a new tab)
Dexlansoprazole label
Version not recorded · Effective date not recorded
Effect on Food In food-effect studies in healthy subjects receiving dexlansoprazole capsules under various fed conditions compared to fasting, increases in C max ranged from 12 to 55%, increases in AUC ranged from 9 to 37%, and T max varied (ranging from a decrease of 0.7 hours to an increase of three hours) [see Dosage and Administration ( 2.3 )].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fc3de800-bfad-4e2f-b664-d58a67550b2f (opens source in a new tab)
Dexlansoprazole label
Version not recorded · Effective date not recorded
Effect on Food In food-effect studies in healthy subjects receiving dexlansoprazole capsules under various fed conditions compared to fasting, increases in C max ranged from 12 to 55%, increases in AUC ranged from 9 to 37%, and T max varied (ranging from a decrease of 0.7 hours to an increase of three hours) [see Dosage and Administration ( 2.3 )].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dcfe880a-b96d-4a3c-aa21-3998d0bcfe9e (opens source in a new tab)
Dexlansoprazole label
Version not recorded · Effective date not recorded
Effect on Food In food-effect studies in healthy subjects receiving dexlansoprazole delayed-release capsules under various fed conditions compared to fasting, increases in C max ranged from 12 to 55%, increases in AUC ranged from 9 to 37%, and T max varied (ranging from a decrease of 0.7 hours to an increase of three hours) [see Dosage and Administration (2.3) ] .
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d7452a26-db20-42fc-868a-a3e3606ca895 (opens source in a new tab)
Dexlansoprazole label
Version not recorded · Effective date not recorded
Effect on Food In food-effect studies in healthy subjects receiving dexlansoprazole capsules under various fed conditions compared to fasting, increases in C max ranged from 12 to 55%, increases in AUC ranged from 9 to 37%, and T max varied (ranging from a decrease of 0.7 hours to an increase of three hours) [see Dosage and Administration ( 2.3 )].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7c7698da-3cda-4301-ae93-02fb64b9c90d (opens source in a new tab)
Dexlansoprazole label
Version not recorded · Effective date not recorded
Effect on Food In food-effect studies in healthy subjects receiving dexlansoprazole delayed-release capsules under various fed conditions compared to fasting, increases in C max ranged from 12 to 55%, increases in AUC ranged from 9 to 37%, and T max varied (ranging from a decrease of 0.7 hours to an increase of three hours) [see Dosage and Administration (2.3) ] .
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8dca4887-c75a-4021-8564-b704e9e1fa3e (opens source in a new tab)
Dexlansoprazole label
Version not recorded · Effective date not recorded
Effect on Food In food-effect studies in healthy subjects receiving dexlansoprazole delayed-release capsules under various fed conditions compared to fasting, increases in C max ranged from 12 to 55%, increases in AUC ranged from 9 to 37%, and T max varied (ranging from a decrease of 0.7 hours to an increase of three hours) [see Dosage and Administration (2.3) ] .
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:59e0c5d7-12e9-b5d7-e063-6394a90a7366 (opens source in a new tab)
Dexlansoprazole label
Version not recorded · Effective date not recorded
Effect on Food In food-effect studies in healthy subjects receiving dexlansoprazole delayed-release capsules under various fed conditions compared to fasting, increases in C max ranged from 12 to 55%, increases in AUC ranged from 9 to 37%, and T max varied (ranging from a decrease of 0.7 hours to an increase of three hours) [see Dosage and Administration (2.3) ] .
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3f9699b5-7614-41cb-bd1d-ff02930e98f3 (opens source in a new tab)
Dexlansoprazole label
Version not recorded · Effective date not recorded
Effect on Food In food-effect studies in healthy subjects receiving dexlansoprazole delayed-release capsules under various fed conditions compared to fasting, increases in C max ranged from 12 to 55%, increases in AUC ranged from 9 to 37%, and T max varied (ranging from a decrease of 0.7 hours to an increase of three hours) [see Dosage and Administration (2.3) ] .
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9819f033-3bbe-442e-8e92-45fec77b237d (opens source in a new tab)
Dexlansoprazole label
Version not recorded · Effective date not recorded
Effect on Food In food-effect studies in healthy subjects receiving DEXILANT under various fed conditions compared to fasting, increases in C max ranged from 12 to 55%, increases in AUC ranged from 9 to 37%, and T max varied (ranging from a decrease of 0.7 hours to an increase of three hours) [see Dosage and Administration (2.3) ] .
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4f44e84f-6219-4445-a67d-df37d18b014d (opens source in a new tab)
Dexlansoprazole label
Version not recorded · Effective date not recorded
Effect on Food In food-effect studies in healthy subjects receiving dexlansoprazole delayed-release capsules under various fed conditions compared to fasting, increases in C max ranged from 12 to 55%, increases in AUC ranged from 9 to 37%, and T max varied (ranging from a decrease of 0.7 hours to an increase of three hours) [see Dosage and Administration (2.3) ] .
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:31d3d485-5f87-4405-b940-490fa4ccf9cc (opens source in a new tab)
Dexlansoprazole label
Version not recorded · Effective date not recorded
Effect on Food In food-effect studies in healthy subjects receiving dexlansoprazole delayed-release capsules under various fed conditions compared to fasting, increases in C max ranged from 12 to 55%, increases in AUC ranged from 9 to 37%, and T max varied (ranging from a decrease of 0.7 hours to an increase of three hours) [see Dosage and Administration (2.3) ] .
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:24c33ba6-bf47-434e-903e-f7ced98e030e (opens source in a new tab)
Dexlansoprazole label
Version not recorded · Effective date not recorded
Effect on Food In food-effect studies in healthy subjects receiving dexlansoprazole under various fed conditions compared to fasting, increases in C max ranged from 12 to 55%, increases in AUC ranged from 9 to 37%, and T max varied (ranging from a decrease of 0.7 hours to an increase of three hours) [see Dosage and Administration (2.3)] .
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f9607c88-03b7-46c6-8b88-84f01dcf2221 (opens source in a new tab)
Dexlansoprazole label
Version not recorded · Effective date not recorded
Effect on Food In food-effect studies in healthy subjects receiving dexlansoprazole under various fed conditions compared to fasting, increases in C max ranged from 12 to 55%, increases in AUC ranged from 9 to 37%, and T max varied (ranging from a decrease of 0.7 hours to an increase of three hours) [see Dosage and Administration (2.3)] .
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3ed69e5a-aa78-4118-aa32-59a10f80c901 (opens source in a new tab)
Dexlansoprazole label
Version not recorded · Effective date not recorded
Effect on Food In food-effect studies in healthy subjects receiving dexlansoprazole capsules under various fed conditions compared to fasting, increases in C max ranged from 12 to 55%, increases in AUC ranged from 9 to 37%, and T max varied (ranging from a decrease of 0.7 hours to an increase of three hours) [see Dosage and Administration ( 2.3 )].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f799b9b6-ba79-f335-e053-6294a90aaa68 (opens source in a new tab)
Dexlansoprazole label
Version not recorded · Effective date not recorded
Effect on Food In food-effect studies in healthy subjects receiving dexlansoprazole delayed-release capsules under various fed conditions compared to fasting, increases in C max ranged from 12 to 55%, increases in AUC ranged from 9 to 37%, and T max varied (ranging from a decrease of 0.7 hours to an increase of three hours) [see Dosage and Administration (2.3) ] .
Projected row 407
- Medicine slug
- dexlansoprazole
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 15
- Source count
- 15
- Agreement rate
- 1
- Recorded readings
40 L
- Numeric value
- 40
- Unit
- L
- Source records
- 15
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 15 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:caad4ada-2cf9-4e12-99df-6ca4388cf0f6 (opens source in a new tab)
Dexlansoprazole label
Version not recorded · Effective date not recorded
The apparent volume of distribution (V z /F) after multiple doses in symptomatic GERD patients was 40 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fc3de800-bfad-4e2f-b664-d58a67550b2f (opens source in a new tab)
Dexlansoprazole label
Version not recorded · Effective date not recorded
The apparent volume of distribution (V z /F) after multiple doses in symptomatic GERD patients was 40 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dcfe880a-b96d-4a3c-aa21-3998d0bcfe9e (opens source in a new tab)
Dexlansoprazole label
Version not recorded · Effective date not recorded
The apparent volume of distribution (V z /F) after multiple doses in symptomatic GERD patients was 40 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d7452a26-db20-42fc-868a-a3e3606ca895 (opens source in a new tab)
Dexlansoprazole label
Version not recorded · Effective date not recorded
The apparent volume of distribution (V z /F) after multiple doses in symptomatic GERD patients was 40 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7c7698da-3cda-4301-ae93-02fb64b9c90d (opens source in a new tab)
Dexlansoprazole label
Version not recorded · Effective date not recorded
The apparent volume of distribution (V z /F) after multiple doses in symptomatic GERD patients was 40 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8dca4887-c75a-4021-8564-b704e9e1fa3e (opens source in a new tab)
Dexlansoprazole label
Version not recorded · Effective date not recorded
The apparent volume of distribution (V z /F) after multiple doses in symptomatic GERD patients was 40 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:59e0c5d7-12e9-b5d7-e063-6394a90a7366 (opens source in a new tab)
Dexlansoprazole label
Version not recorded · Effective date not recorded
The apparent volume of distribution (V z /F) after multiple doses in symptomatic GERD patients was 40 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3f9699b5-7614-41cb-bd1d-ff02930e98f3 (opens source in a new tab)
Dexlansoprazole label
Version not recorded · Effective date not recorded
The apparent volume of distribution (V z /F) after multiple doses in symptomatic GERD patients was 40 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9819f033-3bbe-442e-8e92-45fec77b237d (opens source in a new tab)
Dexlansoprazole label
Version not recorded · Effective date not recorded
The apparent volume of distribution (V z /F) after multiple doses in symptomatic GERD patients was 40 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4f44e84f-6219-4445-a67d-df37d18b014d (opens source in a new tab)
Dexlansoprazole label
Version not recorded · Effective date not recorded
The apparent volume of distribution (V z /F) after multiple doses in symptomatic GERD patients was 40 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:31d3d485-5f87-4405-b940-490fa4ccf9cc (opens source in a new tab)
Dexlansoprazole label
Version not recorded · Effective date not recorded
The apparent volume of distribution (V z /F) after multiple doses in symptomatic GERD patients was 40 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:24c33ba6-bf47-434e-903e-f7ced98e030e (opens source in a new tab)
Dexlansoprazole label
Version not recorded · Effective date not recorded
The apparent volume of distribution (Vz/F) after multiple doses in symptomatic GERD patients was 40 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f9607c88-03b7-46c6-8b88-84f01dcf2221 (opens source in a new tab)
Dexlansoprazole label
Version not recorded · Effective date not recorded
The apparent volume of distribution (Vz/F) after multiple doses in symptomatic GERD patients was 40 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3ed69e5a-aa78-4118-aa32-59a10f80c901 (opens source in a new tab)
Dexlansoprazole label
Version not recorded · Effective date not recorded
The apparent volume of distribution (V z /F) after multiple doses in symptomatic GERD patients was 40 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f799b9b6-ba79-f335-e053-6294a90aaa68 (opens source in a new tab)
Dexlansoprazole label
Version not recorded · Effective date not recorded
The apparent volume of distribution (V z /F) after multiple doses in symptomatic GERD patients was 40 L.
Projected row 408
- Medicine slug
- dexmedetomidine
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 40
- Source count
- 40
- Agreement rate
- 1
- Recorded readings
2 hours
- Numeric value
- 2
- Unit
- hours
- Source records
- 40
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 40 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a99335d0-1e87-4180-bde3-cbb12bf91a52 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following intravenous administration to adults, dexmedetomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (V ss ) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de6f01a2-9f2d-4c68-9c02-06643704acb1 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following intravenous administration, dexmedetomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (V ss ) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9eb336de-5fa5-4b46-b40b-a7ca5a0864bd (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
medetomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t1/2) of approximately 6 minutes; a terminal elimination half-life (t1/2) of approximately 2 hours; and steady-state volume of distribution (Vss) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c116d83f-35da-19ca-e053-2a95a90a017d (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
medetomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t1/2) of approximately 6 minutes; a terminal elimination half-life (t1/2) of approximately 2 hours; and steady-state volume of distribution (Vss) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8fa36783-b94d-4084-8c41-40ee64192074 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following intravenous administration to adults, dexmedetomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (V ss ) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:714cc0d2-8a4c-40c0-8ef0-dcfde4c46989 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following intravenous administration to adults, dexmedetomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (V ss ) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:42dab90e-68c1-bed1-e063-6294a90a4b0c (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following intravenous administration to adults, dexmedetomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (V ss ) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:42cbeadf-fea3-d2ae-e063-6394a90ad549 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
etomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (V ss ) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8ccb45a7-8290-469c-9644-a4dca967d88f (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following intravenous administration to adults, dexmedetomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (V ss ) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1faf1ac8-ff9b-4ed9-b562-06dab971173a (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following intravenous administration to adults, dexmedetomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (V ss ) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eb1ba463-ab42-4f49-9ebe-3ad5af108326 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following intravenous administration to adults, dexmedetomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (V ss ) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:649e777b-9b30-4f1e-9fb9-6bba57580976 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following intravenous administration to adults, dexmedetomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (V ss ) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:32242f34-6e2b-4098-bd8e-3d55162f31b5 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following intravenous administration to adults, dexmedetomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (V ss ) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0d2710f2-ee47-4114-ab5c-8dca74cdcb8d (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following intravenous administration to adults, dexmedetomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (V ss ) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2b9881f0-4a66-660f-e054-00144ff88e88 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
etomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (V ss ) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d174c19d-56f1-4ef4-087c-23c26db8e40b (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following intravenous administration, dexmedetomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (Vss) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ebdfe2e8-30ca-4f18-935a-41bcbbce4937 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following intravenous administration to adults, dexmedetomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (V ss ) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b93a71ed-0f9e-1ff9-e053-2995a90a789d (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
etomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (V ss ) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e9d5c989-ebf6-4377-9c6e-7aef848a03a1 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
Pharmacokinetics Following intravenous administration to adults, dexmedetomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (V ss ) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:92b7ddaa-e45a-4b64-a802-bb5df8771dd6 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following intravenous administration to adults, dexmedetomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (V ss ) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f550d2ba-49ac-4a3b-95db-692b468af479 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following intravenous administration to adults, dexmedetomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (V ss ) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ada70a68-3e52-4b94-e053-2995a90aa1e0 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following intravenous administration, dexmedetomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (V ss ) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a268e759-9a3e-1d7b-e053-2a95a90a335b (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following intravenous administration, dexmedetomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (V ss ) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a2666c50-3b55-1380-e053-2a95a90aea58 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
etomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (V ss ) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:65885aef-faaf-4dec-a180-9a657f738bbc (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following intravenous administration to adults, dexmedetomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (V ss ) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:548a88c0-afda-427e-75ac-5af0cfa2224c (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following intravenous administration to adults, dexmedetomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (V ss ) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eee6145b-d83f-4596-92d3-733934d8a3a4 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following intravenous administration to adults, dexmedetomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (V ss ) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c958aeb4-69ce-c3e2-e053-2a95a90a6d8d (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following intravenous administration to adults, dexmedetomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (V ss ) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:12ef0602-bf07-6ddd-e063-6294a90a23c3 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
etomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (V ss ) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f140de5a-f13d-46b4-a742-049c63e474f5 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following intravenous administration to adults, dexmedetomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (V ss ) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4fe788bc-4ad1-4b32-83d3-dcbfcd8429aa (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following intravenous administration, dexmedetomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (V ss ) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c1b8eb58-596b-481d-beb6-ba9d2237abf4 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following intravenous administration to adults, dexmedetomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (V ss ) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1896a96e-25f8-494e-9a96-6463b52fb102 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following intravenous administration to adults, dexmedetomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (V ss ) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1ee59985-4c1d-48f7-b8f9-5584c2d55e08 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following intravenous administration to adults, dexmedetomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (V ss ) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7d057255-22a1-4b69-ad7c-7337fac8e993 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following intravenous administration to adults, dexmedetomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (V ss ) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8c162541-986b-4b30-866c-b2631ba2c975 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following intravenous administration to adults, dexmedetomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (V ss ) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4419162d-81d4-49bd-96de-1729440bdb74 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following intravenous administration to adults, dexmedetomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (V ss ) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6937235f-ea25-4950-e053-2991aa0a9b74 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following intravenous administration, dexmedetomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (V ss ) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ca67b379-f8b3-4d35-bf8a-235ecd4c4211 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following intravenous administration to adults, dexmedetomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (V ss ) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f307de7e-a9ab-4734-abb7-66b4e112bc51 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following intravenous administration to adults, dexmedetomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (V ss ) of approximately 118 liters.
Projected row 409
- Medicine slug
- dexmedetomidine
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 40
- Source count
- 39
- Agreement rate
- 1
- Recorded readings
94%
- Numeric value
- 94
- Unit
- %
- Source records
- 39
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 39 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a99335d0-1e87-4180-bde3-cbb12bf91a52 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
The average protein binding was 94% and was constant across the different plasma concentrations tested.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de6f01a2-9f2d-4c68-9c02-06643704acb1 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
The average protein binding was 94% and was constant across the different plasma concentrations tested.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c116d83f-35da-19ca-e053-2a95a90a017d (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
The average protein binding was 94% and was constant across the different plasma concentrations tested.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8fa36783-b94d-4084-8c41-40ee64192074 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
The average protein binding was 94% and was constant across the different plasma concentrations tested.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:714cc0d2-8a4c-40c0-8ef0-dcfde4c46989 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
The average protein binding was 94% and was constant across the different plasma concentrations tested.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:42dab90e-68c1-bed1-e063-6294a90a4b0c (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
The average protein binding was 94% and was constant across the different plasma concentrations tested.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:42cbeadf-fea3-d2ae-e063-6394a90ad549 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
The average protein binding was 94% and was constant across the different plasma concentrations tested.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8ccb45a7-8290-469c-9644-a4dca967d88f (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
The average protein binding was 94% and was constant across the different plasma concentrations tested.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1faf1ac8-ff9b-4ed9-b562-06dab971173a (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
The average protein binding was 94% and was constant across the different plasma concentrations tested.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eb1ba463-ab42-4f49-9ebe-3ad5af108326 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
The average protein binding was 94% and was constant across the different plasma concentrations tested.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:649e777b-9b30-4f1e-9fb9-6bba57580976 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
The average protein binding was 94% and was constant across the different plasma concentrations tested.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:32242f34-6e2b-4098-bd8e-3d55162f31b5 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
The average protein binding was 94% and was constant across the different plasma concentrations tested.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0d2710f2-ee47-4114-ab5c-8dca74cdcb8d (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
The average protein binding was 94% and was constant across the different plasma concentrations tested.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2b9881f0-4a66-660f-e054-00144ff88e88 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
The average protein binding was 94% and was constant across the different plasma concentrations tested.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d174c19d-56f1-4ef4-087c-23c26db8e40b (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
The average protein binding was 94% and was constant across the different plasma concentrations tested.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ebdfe2e8-30ca-4f18-935a-41bcbbce4937 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
The average protein binding was 94% and was constant across the different plasma concentrations tested.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b93a71ed-0f9e-1ff9-e053-2995a90a789d (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
The average protein binding was 94% and was constant across the different plasma concentrations tested.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e9d5c989-ebf6-4377-9c6e-7aef848a03a1 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
The average protein binding was 94% and was constant across the different plasma concentrations tested.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:92b7ddaa-e45a-4b64-a802-bb5df8771dd6 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
The average protein binding was 94% and was constant across the different plasma concentrations tested.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f550d2ba-49ac-4a3b-95db-692b468af479 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
The average protein binding was 94% and was constant across the different plasma concentrations tested.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ada70a68-3e52-4b94-e053-2995a90aa1e0 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
The average protein binding was 94% and was constant across the different plasma concentrations tested.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a268e759-9a3e-1d7b-e053-2a95a90a335b (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
The average protein binding was 94% and was constant across the different plasma concentrations tested.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a2666c50-3b55-1380-e053-2a95a90aea58 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
The average protein binding was 94% and was constant across the different plasma concentrations tested.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:65885aef-faaf-4dec-a180-9a657f738bbc (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
The average protein binding was 94% and was constant across the different plasma concentrations tested.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:548a88c0-afda-427e-75ac-5af0cfa2224c (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
The average protein binding was 94% and was constant across the different plasma concentrations tested.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eee6145b-d83f-4596-92d3-733934d8a3a4 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
The average protein binding was 94% and was constant across the different plasma concentrations tested.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c958aeb4-69ce-c3e2-e053-2a95a90a6d8d (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
The average protein binding was 94% and was constant across the different plasma concentrations tested.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:12ef0602-bf07-6ddd-e063-6294a90a23c3 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
The average protein binding was 94% and was constant across the different plasma concentrations tested.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f140de5a-f13d-46b4-a742-049c63e474f5 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
The average protein binding was 94% and was constant across the different plasma concentrations tested.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4fe788bc-4ad1-4b32-83d3-dcbfcd8429aa (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
The average protein binding was 94% and was constant across the different plasma concentrations tested.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c1b8eb58-596b-481d-beb6-ba9d2237abf4 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
The average protein binding was 94% and was constant across the different plasma concentrations tested.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1896a96e-25f8-494e-9a96-6463b52fb102 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
The average protein binding was 94% and was constant across the different plasma concentrations tested.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1ee59985-4c1d-48f7-b8f9-5584c2d55e08 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
The average protein binding was 94% and was constant across the different plasma concentrations tested.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7d057255-22a1-4b69-ad7c-7337fac8e993 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
The average protein binding was 94% and was constant across the different plasma concentrations tested.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8c162541-986b-4b30-866c-b2631ba2c975 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
The average protein binding was 94% and was constant across the different plasma concentrations tested.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4419162d-81d4-49bd-96de-1729440bdb74 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
The average protein binding was 94% and was constant across the different plasma concentrations tested.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6937235f-ea25-4950-e053-2991aa0a9b74 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
The average protein binding was 94% and was constant across the different plasma concentrations tested.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ca67b379-f8b3-4d35-bf8a-235ecd4c4211 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
The average protein binding was 94% and was constant across the different plasma concentrations tested.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f307de7e-a9ab-4734-abb7-66b4e112bc51 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
The average protein binding was 94% and was constant across the different plasma concentrations tested.
Projected row 410
- Medicine slug
- dexmedetomidine
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 40
- Source count
- 40
- Agreement rate
- 1
- Recorded readings
118 liters
- Numeric value
- 118
- Unit
- L
- Source records
- 40
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 40 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a99335d0-1e87-4180-bde3-cbb12bf91a52 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following intravenous administration to adults, dexmedetomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (V ss ) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de6f01a2-9f2d-4c68-9c02-06643704acb1 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following intravenous administration, dexmedetomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (V ss ) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9eb336de-5fa5-4b46-b40b-a7ca5a0864bd (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
apid distribution phase with a distribution half-life (t1/2) of approximately 6 minutes; a terminal elimination half-life (t1/2) of approximately 2 hours; and steady-state volume of distribution (Vss) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c116d83f-35da-19ca-e053-2a95a90a017d (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
apid distribution phase with a distribution half-life (t1/2) of approximately 6 minutes; a terminal elimination half-life (t1/2) of approximately 2 hours; and steady-state volume of distribution (Vss) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8fa36783-b94d-4084-8c41-40ee64192074 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following intravenous administration to adults, dexmedetomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (V ss ) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:714cc0d2-8a4c-40c0-8ef0-dcfde4c46989 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following intravenous administration to adults, dexmedetomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (V ss ) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:42dab90e-68c1-bed1-e063-6294a90a4b0c (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following intravenous administration to adults, dexmedetomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (V ss ) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:42cbeadf-fea3-d2ae-e063-6394a90ad549 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (V ss ) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8ccb45a7-8290-469c-9644-a4dca967d88f (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following intravenous administration to adults, dexmedetomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (V ss ) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1faf1ac8-ff9b-4ed9-b562-06dab971173a (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following intravenous administration to adults, dexmedetomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (V ss ) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eb1ba463-ab42-4f49-9ebe-3ad5af108326 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following intravenous administration to adults, dexmedetomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (V ss ) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:649e777b-9b30-4f1e-9fb9-6bba57580976 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following intravenous administration to adults, dexmedetomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (V ss ) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:32242f34-6e2b-4098-bd8e-3d55162f31b5 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following intravenous administration to adults, dexmedetomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (V ss ) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0d2710f2-ee47-4114-ab5c-8dca74cdcb8d (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following intravenous administration to adults, dexmedetomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (V ss ) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2b9881f0-4a66-660f-e054-00144ff88e88 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (V ss ) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d174c19d-56f1-4ef4-087c-23c26db8e40b (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following intravenous administration, dexmedetomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (Vss) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ebdfe2e8-30ca-4f18-935a-41bcbbce4937 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following intravenous administration to adults, dexmedetomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (V ss ) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b93a71ed-0f9e-1ff9-e053-2995a90a789d (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (V ss ) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e9d5c989-ebf6-4377-9c6e-7aef848a03a1 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
Pharmacokinetics Following intravenous administration to adults, dexmedetomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (V ss ) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:92b7ddaa-e45a-4b64-a802-bb5df8771dd6 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following intravenous administration to adults, dexmedetomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (V ss ) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f550d2ba-49ac-4a3b-95db-692b468af479 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following intravenous administration to adults, dexmedetomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (V ss ) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ada70a68-3e52-4b94-e053-2995a90aa1e0 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following intravenous administration, dexmedetomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (V ss ) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a268e759-9a3e-1d7b-e053-2a95a90a335b (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following intravenous administration, dexmedetomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (V ss ) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a2666c50-3b55-1380-e053-2a95a90aea58 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (V ss ) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:65885aef-faaf-4dec-a180-9a657f738bbc (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following intravenous administration to adults, dexmedetomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (V ss ) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:548a88c0-afda-427e-75ac-5af0cfa2224c (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following intravenous administration to adults, dexmedetomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (V ss ) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eee6145b-d83f-4596-92d3-733934d8a3a4 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following intravenous administration to adults, dexmedetomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (V ss ) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c958aeb4-69ce-c3e2-e053-2a95a90a6d8d (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following intravenous administration to adults, dexmedetomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (V ss ) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:12ef0602-bf07-6ddd-e063-6294a90a23c3 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (V ss ) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f140de5a-f13d-46b4-a742-049c63e474f5 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following intravenous administration to adults, dexmedetomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (V ss ) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4fe788bc-4ad1-4b32-83d3-dcbfcd8429aa (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following intravenous administration, dexmedetomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (V ss ) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c1b8eb58-596b-481d-beb6-ba9d2237abf4 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following intravenous administration to adults, dexmedetomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (V ss ) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1896a96e-25f8-494e-9a96-6463b52fb102 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following intravenous administration to adults, dexmedetomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (V ss ) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1ee59985-4c1d-48f7-b8f9-5584c2d55e08 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following intravenous administration to adults, dexmedetomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (V ss ) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7d057255-22a1-4b69-ad7c-7337fac8e993 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following intravenous administration to adults, dexmedetomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (V ss ) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8c162541-986b-4b30-866c-b2631ba2c975 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following intravenous administration to adults, dexmedetomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (V ss ) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4419162d-81d4-49bd-96de-1729440bdb74 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following intravenous administration to adults, dexmedetomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (V ss ) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6937235f-ea25-4950-e053-2991aa0a9b74 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following intravenous administration, dexmedetomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (V ss ) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ca67b379-f8b3-4d35-bf8a-235ecd4c4211 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following intravenous administration to adults, dexmedetomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (V ss ) of approximately 118 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f307de7e-a9ab-4734-abb7-66b4e112bc51 (opens source in a new tab)
Dexmedetomidine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following intravenous administration to adults, dexmedetomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t 1/2 ) of approximately 6 minutes; a terminal elimination half-life (t 1/2 ) of approximately 2 hours; and steady-state volume of distribution (V ss ) of approximately 118 liters.
Access
Query or download the projection
GET /api/datasets/source-consensus?limit=10&offset=400Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- state
- Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
- field
- Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.